Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Nasdaq

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse ...
GEN

As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...
GEN

Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease

Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...
The Motley Fool

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...